[144] CORCEPT THERAPEUTICS INC SEC Filing

Rhea-AI Filing Summary

Corcept Therapeutics Inc. insider plans another share sale. A Form 144 notice discloses an intended sale of up to 20,000 shares of Corcept common stock through Stifel Nicolaus & Company Inc. on or about 01/06/2026, with an indicated aggregate market value of $699,000.00. The filing notes that 105,190,000 Corcept common shares were outstanding, providing context for the size of the planned transaction.

The 20,000 shares to be sold were acquired on 01/06/2026 via a stock option exercise from Corcept Therapeutics Inc., paid in cash. Over the prior three months, the same seller, William Guyer, reported three separate sales of 20,000 Corcept common shares each (on 10/07/2025, 11/05/2025, and 12/02/2025) with gross proceeds of $1,798,781.00, $1,507,121.00, and $1,601,525.00, respectively.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Company Inc. 501 N. Broadway St. Louis MO 63102	20000	699000.00	105190000	01/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/06/2026	Stock Option Exercise	Corcept Therapeutics Inc.			20000	01/06/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	12/02/2025	20000	1601525.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	10/07/2025	20000	1798781.00
William Guyer 101 Redwood Shores Parkway Redwood City CA 94065	Common	11/05/2025	20000	1507121.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)